Biovica appoints Anders Morén as CFO

2022-10-20 08:00

Biovica, active in cancer diagnostics, today announces that Anders Morén has been appointed as the company’s Chief Financial Officer (CFO). Anders Morén will begin his new position on January 1, 2023.

Most recently, Anders Morén comes from the global pharmaceutical company Gilead where he was responsible for the finance function for a large part of Europe, Middle East and Africa (EMEA, with over SEK 10 billion in annual sales).

"I am very happy to welcome Anders Morén to Biovica. Among other things, he has participated in several successful launches at Gilead, experiences that will be very valuable to us when we launch DiviTum®TKa on the American market. I am very proud of the strong team Biovica has built and am humbled by the competent people we have managed to attract," said Anders Rylander, CEO of Biovica.

"I am very much looking forward to being part of the exciting journey that Biovica is facing. Based on my many years in the pharmaceutical industry, I hope to be able to contribute to the continued development of the company. The goal is to switch up and manage various opportunities to create future value, both for patients and shareholders,” said Anders Morén, the next CFO of Biovica.

Anders Morén succeeds Cecilia Driving, who, as previously announced, is leaving Biovica on December 31, 2022.

Some of our Collaborations

>3200

Numbers of patients in studies

24

Publications

10

Pharma Contracts